Prime Global
Prime Global, a medical communications group with offices in the US and the UK, has appointed Sue O’Leary (pictured left) to lead their growing market access practice. She will also support the business across the group’s six full service medical communications agencies.
Also joining O’Leary at Prime Global is Rebecca Massey (pictured below, right), who has been appointed as senior director, global market access & HEOR.
O’Leary will report to chief executive officer and chairman of Prime Global, Graeme Peterson. He commented: “We are thrilled to welcome Sue and Rebecca to Prime Global – their expertise will provide an even stronger platform from which to deliver brilliant strategic and communication solutions for our pharma clients worldwide.”
Both O’Leary and Massey have experience of delivering evidence-based pricing and market access communications to help build global brands.
They also have additional experience of the challenges in an evolving payer environment, gained in prior roles in the NHS, the pharma industry and market access consulting.
Swordfish Advertising
Swordfish Advertising, a pharmaceutical and veterinary healthcare advertising agency, has promoted two senior members of its client services team.
Sarah Rush (pictured below, right) has been appointed as client services director, and has over ten years of experience in healthcare communications.
She has worked with global brands including Sanofi Genzyme and Novartis. In her new role, Rush will work closely with the company directors – John Bohin and Ilya Todd – to lead the client services team as it faces the continued expansion of its client work.
Sarah Vickery (left) and Sarah Rush (right)
Also being promoted is Sarah Vickery (pictured above, left), who has been appointed as group account director. She has over ten years of experience within the healthcare sector, and has successfully managed a number of accounts for the agency, including both global and UK clients.
Wilmington Healthcare
Wilmington Healthcare – a healthcare intelligence provider which incorporates HSJ, Interactive Medica and OnMedica – has expanded its team with the appointments of two senior consultants.
Roger Tomlins (pictured right), who joins Wilmington from Bristol-Myers Squibb, has worked in healthcare for over 16 years, in both the pharmaceutical industry and the NHS. At BMS, he worked as senior regional access manager and led new customer-focused initiatives in cardiology and oncology.
Prior to BMS, he worked for Pfizer Essential Health, as a clinical effectiveness consultant. Tomlins also has NHS experience, having worked for the Royal Berkshire NHS Foundation Trust as a general/operations manager for four years.
Also joining Wilmington is Sarah Shield (pictured left), who has worked in the pharmaceutical industry for 14 years.
She has a wealth of experience in providing consultancy on market access, strategic partnerships, clinical policy development and government affairs.
Prior to joining the team at Wilmington, Shield was national policy and partnership lead for AstraZeneca’s UK cardiovascular and renal franchise. In that role, she provided strategic insight on NHS policies, commissioning and reimbursement pathways.
Before AstraZeneca, she worked for GlaxoSmithKline for four years in a number of roles, including therapy specialist for its allergy portfolio.
Gareth Thomas, managing director of Wilmington Healthcare, said: “Having worked in diverse roles within the healthcare sector, Roger and Sarah bring a wealth of knowledge and experience to their new posts.
“They are perfectly placed to help our clients keep pace with the scale and speed of change within the NHS and create compelling propositions. They will be a great asset to our consultancy team, and we’re delighted to be working with them,” he added.